Cargando…

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blom, Thomas, Lurvink, Roosmarijn, Aleven, Leonie, Mensink, Maarten, Wolfs, Tom, Dierselhuis, Miranda, van Eijkelenburg, Natasha, Kraal, Kathelijne, van Noesel, Max, van Grotel, Martine, Tytgat, Godelieve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925836/ https://www.ncbi.nlm.nih.gov/pubmed/33680926 http://dx.doi.org/10.3389/fonc.2020.601076

Ejemplares similares

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
por: Tas, Michelle L., et al.
Publicado: (2021)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
por: Szanto, Celina L., et al.
Publicado: (2021)

Imaging features of hepatic sinusoidal obstruction syndrome or veno-occlusive disease in children
por: Bohte, Anneloes E., et al.
Publicado: (2021)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

[(18)F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2022)

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
por: Samim, Atia, et al.
Publicado: (2021)

Correction to: [(18)F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2023)

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
por: van Wezel, Esther M., et al.
Publicado: (2019)

Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis
por: Nijstad, A. Laura, et al.
Publicado: (2020)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Correction to: Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo‑continuous arterial spin‑labelling magnetic resonance imaging
por: Harteveld, Anita, et al.
Publicado: (2021)

Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo-continuous arterial spin-labelling magnetic resonance imaging
por: Harteveld, Anita Adriaantje, et al.
Publicado: (2021)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort
por: Tas, Michelle L., et al.
Publicado: (2022)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring
por: Gelineau, Nina U., et al.
Publicado: (2023)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells
por: Hochheuser, Caroline, et al.
Publicado: (2020)

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies
por: M. Kholosy, Waleed, et al.
Publicado: (2021)

Two opposing gene expression patterns within ATRX aberrant neuroblastoma
por: van Gerven, Michael R., et al.
Publicado: (2023)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
por: Spel, Lotte, et al.
Publicado: (2015)

Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
por: Sabbih, Godfred O., et al.
Publicado: (2021)

Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
por: van Zogchel, Lieke M. J., et al.
Publicado: (2020)

MRI-based inter- and intrafraction motion analysis of the pancreatic tail and spleen as preparation for adaptive MRI-guided radiotherapy in neuroblastoma
por: Van Ommen, Fasco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9qn37rpfdltaav4r86l63hl43h